Phar­ma en­ters ‘age of un­cer­tain­ty’ amid chal­lenges from IRA, FTC and patent cliffs

It’s been a de­mand­ing year for the phar­ma in­dus­try. There’s a more ag­gres­sive FTC, a chang­ing FDA, tough mar­ket con­di­tions, and a le­gal fight over the drug pric­ing pro­vi­sions in the In­fla­tion Re­duc­tion Act.

Wel­come to phar­ma’s “age of un­cer­tain­ty,” ac­cord­ing to Eval­u­ate’s lat­est re­port, which de­scribes a world in which “work­ing out what kind of as­sets to de­vel­op or buy has be­come much more com­pli­cat­ed.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER